Personalized Treatment Strategies in the Management of Castration-Resistant Prostate Cancer

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2020 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from November 1, 2020 to March 1, 2022

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
AstraZeneca, Clovis Oncology, Merck Sharp & Dohme Corp., and Sanofi

Description:
Prostate cancer is the most commonly diagnosed noncutaneous cancer in men in the United States and remains the second leading cause of cancer deaths among American men, with an estimated 174,000 new cases diagnosed in 2019. Prostate cancer deaths are typically the result of castration-resistant prostate cancer (CRPC), and most patients will eventually experience disease progression despite castration, with a median duration of response of 12–24 months. Patients with all stages of prostate cancer have many treatment options available to them, from front-line therapy to second-line therapy and beyond with both immunotherapy and chemotherapy as current options. Recently updated guidelines on optimal sequencing and switching of antiandrogens, chemotherapy, immunotherapy, biomarkers and appropriate patient selection criteria in patients with prostate cancer have been produced and are being used to better treat the disease. The measurement of PSA level has also recently improved the diagnosis of prostate cancer, which is important because it helps identify patients who have prostate cancer and are undertreated. This marker is used for early diagnosis and monitoring for disease recurrence. PSA is the most common biochemical marker for prostate cancer and is used as a screening tool, although it remains prostate specific and not necessarily prostate cancer specific.

The advances in the past few years have resulted in the investigations of several novel targeted therapies, including androgen receptor inhibitor (ARI) targeting agents, antineoplastic agent and gonadotropin releasing hormone agonist, tyrosine kinase inhibitors (TKIs), antiangiogenic agents, endothelin receptor antagonists, anti-apoptotic protein inhibitors and proteasome inhibitors. There are also updated options for treatments being used to improve outcomes for hormone sensitive prostate cancer. Several of these options have either received approval from the FDA or are in late clinical trials based on improvement of intermediate surrogate endpoints such as PSA levels or circulating tumor cell (CTC) counts in recent clinical trials.

Upon completion of this activity, participants will be able to:

  • Assess evidence-based recommendations for use of current and novel agents for metastatic castration-resistant prostate cancer (CRPC) management

  • Evaluate appropriate diagnostic strategies, including biomarkers and molecular assay testing, to assess risk and prognosis in patients with prostate cancer

  • Analyze emerging efficacy and safety data on novel therapeutic strategies for patients with CRPC, including findings on novel combination and sequential treatment options

  • Explore the recent evidence supporting the PARP inhibitor treatment options

  • Implement strategies to overcome challenges in patients with CRPC, including adherence, adverse events, and effective physician-patient communication strategies

  • Apply methods to enable optimal cost management of CRPC treatments, including PARP inhibitors, to be realized by prostate cancer stakeholders including managed care organizations

     

Faculty: Daniel P. Petrylak, MD
Professor of Medicine, Medical Oncology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Group
Yale Cancer Center

Disclosure:

Dr. Petrylak serves as a consultant for Advanced Accelerator Applications, Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis Oncology, Eli Lilly, Exelixis, Incyte, Janssen, Mirati, Monopteros, Pfizer, Pharmacyclics, Roche, Seattle Genetics, and Urogen. He has received grant/research support from Advanced Accelerator Applications, Agensys Inc, Astellas, AstraZeneca, Bayer, BioXcel Therapeutics, Bristol-Myers Squibb, Clovis Oncology, Eisai, Eli Lilly,Endocyte, Genentech, Innocrin, MedImmune, Medivation, Merck, Mirati,Novartis, Pfizer, Progenics, Replimune, Roche, Sanofi, and Seattle Genetics. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
AstraZeneca, Clovis Oncology, Merck Sharp & Dohme Corp., and Sanofi

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue